Three ways to work with the FDA for better patient-focused trials
Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.
This article covers three useful practices for getting the most out of your collaboration.
Related Insights
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022
Video
A Life in a Day
Jul 28, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Video
Nurse Advisory Panel
Jul 13, 2022
Video
Parexel Site Alliances
Jul 13, 2022
Related Insights
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Blog
Taking a Proactive Approach to Post-Launch Patient Accessibility in Strategic Planning
Aug 4, 2022
Video
A Life in a Day
Jul 28, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Video
Nurse Advisory Panel
Jul 13, 2022
Video
Parexel Site Alliances
Jul 13, 2022